

Quantitative CT Helps Identify COPD Patients at Risk for Exacerbations

JANUARY 02, 2012

DENVER, CO — National Jewish Health researchers and their colleagues in the COPDGene research consortium report that a computerized form of radiology, known as quantitative CT, can offer valuable prognostic information for patients and doctors beyond the standard breathing tests most commonly used to evaluate [chronic obstructive pulmonary disease](#) (COPD).

“Our findings indicate that quantitative CT scans can help identify patients at greater risk for damaging exacerbations of their disease,” said James D. Crapo, MD, Professor of Medicine at National Jewish Health and co-author of the paper that appeared in the October 2011 issue of *Radiology*. “The findings also help us identify distinct phenotypes among the COPD patient population, who could benefit from individualized, targeted management of their disease.”

Progression of COPD does not occur at a steady rate. Exacerbations, flare-ups of the disease sometimes requiring hospitalization, accelerate the decline in lung function, increase the risk of death and lower quality of life. Being able to identify patients at greater risk of exacerbations, and possibly prevent them is an important goal in care of COPD patients.

Breathing tests, known as spirometry, are the standard tool for evaluating and staging COPD. Although worse results on spirometry do broadly correlate with exacerbations, there are many exceptions. For this and other reasons, physicians have been seeking better tools to evaluate their COPD patients.

The COPDGene research team sought to evaluate the ability of radiologic imaging to be that tool. They used [quantitative CT](#), a computerized method of measuring lighter and darker areas of the scan, to measure inflammation as determined by thickness of airway walls and the amount of tissue destruction or emphysema.

They found that greater airway wall thickness and emphysema were both associated with more frequent exacerbations. Each 1 millimeter increase in bronchial wall thickness was associated with a 1.84-fold increase in annual exacerbation rate. Emphysema became a factor only if it involved 35 percent or more of the lungs. Beyond the 35 percent involvement, each 5 percent increase in emphysema was associated with a 1.18-fold increase in exacerbations.

“Quantitative CT scans can help identify patients at greater risk for exacerbations independent of their spirometry results,” said Dr. Crapo. “This could be valuable in identifying specific individuals for targeted medical therapy.”

National Jewish Health is the leading respiratory hospital in the nation. Founded 125 years ago as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of children and adults with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit the [media resources](#) page.

Media Resources

Media Contacts

We have many faculty members, from bench scientists to clinicians, who can speak on almost any aspect of respiratory, immune, cardiac and gastrointestinal disease as well as lung cancer and basic immunology.

- [Accomplishments & Awards](#)
- [Annual Report](#)
- [Financials](#)

Our team is available to arrange interviews, discuss events and story ideas.

Adam Dormuth

[303.398.1002](tel:303.398.1002) office

[970.222.5034](tel:970.222.5034) mobile

dormutha@njhealth.org

Jessica Berry

[303.398.1082](tel:303.398.1082) office

[303.807.9491](tel:303.807.9491) mobile

berryj@njhealth.org